---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-120789"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:13:02.645371+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Palvella Phase 2 TOIVA study: 73% of patients improved; plans FDA discussions for Breakthrough Therapy

## Summary
- 73% (11/15) improved on Overall cVM-IGA at Week 12; 67% rated "Much Improved" or "Very Much Improved".
- Statistical significance on multiple endpoints, including Overall cVM-IGA (p<0.001) and PGI-C (p<0.001).
- QTORIN rapamycin generally well-tolerated; no drug-related SAEs; most common AE application site erythema (25%).
- Company plans near-term FDA discussions for Breakthrough Therapy Designation and Phase 3 pivotal study.
- Potential first FDA-approved therapy for cutaneous venous malformations affecting >75,000 patients in US.

## SEC filing metadata
- accession: 0001104659-25-120789
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/0001104659-25-120789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/tm2533458d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-120789
- JSON: https://secwatch.observer/filing/0001104659-25-120789.json
- Plain text: https://secwatch.observer/filing/0001104659-25-120789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.